Meeting
2022 ASCO Annual Meeting
A phase II study to evaluate the safety and efficacy of radiotherapy combined with irinotecan liposome followed by camrelizumab and apatinib for advanced solid tumors that failed standard treatments.
Authors
Jie Shen
The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Jie Shen , Rutian Li , Jing Yan , Juan Du , Jia Wei , Sihui Zhu , Ying Liu , Huajun Li , Baorui Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT04569916
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2567)
DOI
10.1200/JCO.2022.40.16_suppl.2567
Abstract #
2567
Poster Bd #
222
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Clinical study on the second-line treatment of advanced esophageal squamous cell carcinoma with camrelizumab combined with apatinib and irinotecan: A single-arm, multicenter, phase II study.
First Author: Yifu He
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Camrelizumab plus apatinib after progression on immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma (CAP 02 Re-challenge): A single-arm multicenter, phase II trial.
First Author: Xiangrui Meng
Poster
2023 ASCO Annual Meeting
A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.
First Author: Sheng Li